Abstract
BackgroundBispecific antibodies (BsAbs) are an important class of therapeutics for immune-oncology applications. T cell engagers (TCEs) target tumor-associated antigens and cytotoxic T cells to eradicate antigen-expressing tumor cells. Blinatumomab (CD19...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
